Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1653 1675 1681 1693
This examiner grants 55% of resolved cases
Erin M. Bowers handles cases in Tech Center 1600 and Art Unit 1653, where she has 550 resolved cases. Her allowance rate is 54.7 percent, indicating a competitive examination environment where a portion of the applications result in a grant. The median days to allowance is 1290, suggesting a prolonged prosecution period for those seeking a patent.
Practitioners can improve their chances of success by utilizing examiner interviews, which provide an interview lift of 10.6 percent. This lift is a meaningful increase over the 54.7 percent baseline allowance rate, suggesting that direct communication is an effective strategy for resolving rejections in these 550 resolved cases. The 1290 median days to allowance should be factored into the overall patent strategy.
In Art Unit 1653, the 54.7 percent allowance rate and the 10.6 percent interview lift highlight the importance of active engagement. Because the median days to allowance is 1290, applicants must be prepared for a lengthy commitment to reach a resolution. The data from the 550 resolved cases suggests that while the path is long, interviews offer a statistical advantage for securing an allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18611181 | TWO COMBINED MUTATIONS THAT INTRODUCE THE SECOND ENTRY PATHWAY TO SYNTHESIZED LIGNIN FROM TYROSINE IN PLANTS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 16821807 | NOVEL EUKARYOTIC CELL-FREE PROTEIN EXPRESSION SYSTEM THAT DOES NOT REQUIRE AN ARTIFICIAL ENERGY REGENERATION SYSTEM | Final Rejection | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
| 18654695 | PROCASPASE-CLEAVING PROTEASES AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 18667369 | STABLE THERMOLYSIN HYDROGEL | Final Rejection | SMITH & NEPHEW, INC. |
| 17057939 | AGROCHEMICAL FORMULATIONS CONTAINING A POLYMERIC CRYSTAL GROWTH INHIBITOR | Non-Final OA | Bayer Aktiengesellschaft |
| 18593314 | CONJUGATES AND METHODS OF USE THEREOF | Non-Final OA | Regents of the University of Minnesota |
| 18626999 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR DISEASE | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18597113 | DELIGNIFIED BAMBOO SCAFFOLDS INCLUDING IMMOBILIZED ENZYMES AND METHODS FOR FORMING AND USING SAME | Non-Final OA | UNIVERSITY OF SOUTH CAROLINA |
| 18599502 | TARGETS AND BIOMARKERS FOR TUMOR MICROENVIRONMENTS | Non-Final OA | The Trustees of Indiana University |
| 18599563 | Deep Eutectic Solvent Stabilized Enzyme-Based Electrochemical Assay Probes for Use in the Field | Non-Final OA | The Government of the United States of America, as represented by the Secretary of the Navy |
| 17920561 | METHOD OF REDUCING AND RECYCLING OXIDIZED FLAVIN COFACTORS | Final Rejection | Oxford University Innovation Limited |
| 18700134 | ENDOGLUCANASE WITH IMPROVED STABILITY | Non-Final OA | Novozymes A/S |
| 18355437 | Distributed Ribonucleic Acid Manufacturing Via Enzymatic Reaction And Separation | Non-Final OA | Drexel University |
| 18307144 | SECRETION OF HEME-CONTAINING POLYPEPTIDES | Final Rejection | Impossible Foods Inc. |
| 18658276 | EXTRAMAMMARY PAGET DISEASE BIOMARKERS AND USES THEREOF | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18655005 | COMPLEMENTATION-BASED TAGS AND REPORTERS FOR DUAL-MODALITY LABELING | Non-Final OA | Promega Corporation |
| 18312117 | SPLIT MODIFIED DEHALOGENASE VARIANTS | Non-Final OA | Promega Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy